Home
News
Create
Screeners
Insights
Gufic BioSciences
278.
55
-4.50
(-1.59%)
Market Cap
₹2,793.37 Cr
PE Ratio
56.44
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.59%
1M
-7.01%
6M
-26.10%
1Y
-16.96%
5Y
+133.58%
View Company Insights
Latest news about Gufic BioSciences
Gufic Biosciences Releases Q3FY26 Investor Presentation with Financial Results
Feb 10, 2026
Gufic Biosciences reported Q3FY26 revenue of ₹231.10 crore, up 11.22% year-on-year, though profit margins declined with PAT falling to ₹15.60 crore. The company's Indore facility achieved 30% capacity utilization with production capabilities across multiple injectable formats, while maintaining strong regulatory compliance across its diversified pharmaceutical platform.
Gufic Biosciences Receives Income Tax Demand of ₹4.33 Crores for Assessment Year 2024-25
Jan 20, 2026
Gufic Biosciences Receives GST Penalty Order of ₹15.64 Lakh for FY2018-19 to FY2022-23
Dec 27, 2025
Gufic Biosciences Reports Q1 Results: Revenue Up, Profit Down Amid Rising Costs
Aug 13, 2025
Gufic Biosciences Reports Mixed Q4 Results: Revenue Up, Profits Down
May 30, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO